Needham & Company
-
Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal
-
Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
-
Needham & Company Reiterates Buy on Summit Therapeutics (SMMT) Following World Muscle Society Meeting
-
Summit Therapeutics (SMMT) SMT C1100 Fully Enrolled in Trial Phase Ib; Needham & Company Reiterates Buy
-
Summit to Present at Needham and Company's Annual Healthcare Conference
-
Needham & Company Starts Summit Therapeutics plc (SMMT) at Buy
-
Summit Therapeutics Announces Exercise of Over-Allotment Option
-
Summit Therapeutics Announces Closing of Its U.S. Initial Public Offering
-
Summit Therapeutics (SMMT) IPO Opens Fractionally Higher

